Gilead Sciences (GILD) P/E (2009 - 2026)
Gilead Sciences (GILD) P/E from Mar 31, 2009 to Jul 21, 2026. The TTM Gilead Sciences (GILD) P/E is 17.55. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/E
Annual P/E change of Gilead Sciences (GILD)
| Year | P/E | Change |
|---|---|---|
| 2026 | 17.55 | -2.02% |
| 2025 | 17.92 | -92.53% |
| 2024 | 239.78 | +1294.28% |
| 2023 | 17.20 | -46.74% |
| 2022 | 32.29 | +120.69% |
| 2021 | 14.63 | -97.53% |
| 2020 | 592.58 | +3769.74% |
| 2019 | 15.31 | +3.02% |
| 2018 | 14.86 | +84.09% |
| 2017 | 8.07 | +24.99% |
| 2016 | 6.46 | -20.51% |
| 2015 | 8.13 | -31.24% |
| 2014 | 11.82 | -68.38% |
| 2013 | 37.38 | +74.03% |
| 2012 | 21.48 | +69.94% |
| 2011 | 12.64 | +23.19% |
| 2010 | 10.26 | -30.83% |
| 2009 | 14.83 | N/A |
Comparison Gilead Sciences (GILD) P/E with competitors
Gilead Sciences (GILD) P/E is 17.55.
| Ticker | Name | P/E | Upside |
|---|---|---|---|
| GRFS | Grifols SA | 10.11 | -42.41% |
| PFE | Pfizer Inc | 11.65 | -33.61% |
| NVO | Novo Nordisk | 11.79 | -32.83% |
| GSK | GSK Plc | 12.10 | -31.05% |
| SNY | Sanofi | 12.12 | -30.93% |
| BMY | Bristol-Myers Squibb Company | 13.82 | -21.27% |
| OGN | Organon & Company | 14.33 | -18.38% |
| BIIB | Biogen Inc | 17.41 | -0.84% |
| NVS | Novartis AG | 21.60 | +23.03% |
| JNJ | Johnson & Johnson | 22.09 | +25.83% |
| AMGN | AMGEN Inc | 24.75 | +41.00% |
| MRK | Merck & Co Inc | 26.93 | +53.40% |
| AZN | Astrazeneca plc | 28.44 | +62.03% |
| LLY | Lilly(Eli) & Company | 48.44 | +175.97% |
| ABBV | Abbvie Inc | 139.08 | +692.32% |